For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > BUSINESS
BUSINESS
- PTH Preparations, New Drugs Grow in Intense Anti-Osteoporosis Drug Competition
July 10, 2013
- Kyowa Kirin Aims to Lead the Domestic Parkinson’s Disease Market in 5 Years on the Strength of Nouriast and 3 Other Products
July 10, 2013
- Will the ARB Market Regain Steam in FY2013? Leading ARB Drug Marketers Forecast Double-digit Growth in FY2013
July 10, 2013
- High Price, Concerns About Safety Could Pose Hurdle to Success of Pfizer Japan’s Xeljanz
July 10, 2013
- Kyowa Kirin Steps into Diabetes Market with 7th DPP-4 Inhibitor Onglyza
July 9, 2013
- CMIC Subsidiary SSI to Set Up Committee to Investigate Suspected Clinical Data Manipulation
July 9, 2013
- Ethical Drug Sales Up 3.3% in May: Crecon Report
July 9, 2013
- Kyorin to Merge 2 Domestic Development Sites in Tochigi Prefecture
July 8, 2013
- Daiichi Sankyo to Promote Osteoporosis Treatment Pralia with Focus on Appropriate Use
July 5, 2013
- Over 60% of Cancer Patients Aware of Generic Cancer Treatment Options: Sawai Survey
July 5, 2013
- Fujifilm to Begin PIII Study of Personalized Peptide Cancer Vaccine
July 5, 2013
- AY Pharmaceuticals Starts Operations, Yoshindo Bolsters Sales, Marketing System
July 5, 2013
- Hanshin DP Holdings, Medical System Network Establish New JV to Support Efficient Distribution
July 5, 2013
- Importance of Personal Relationships, Low Use of Generics Contribute to Persistence of SOV Model in Japan, but Change is Likely
July 5, 2013
- MTPC Begins Construction of New Head Office Building, Expects Completion in January 2015
July 4, 2013
- Generic Industry Needs to Produce 30 Billion More Tablets to Meet 60% Generic Share Goal: Sawai President
July 4, 2013
- Out-Licensed OAB Treatment Imidafenacin Launched in South Korea: Kyorin Holdings
July 4, 2013
- Low-Dose Lunabell Approved
July 4, 2013
- Manipulation of BMI Data in Kobayashi Pharmaceutical’s Anti-Obesity Drug Clinical Study Suspected
July 3, 2013
- Sandoz to Ratchet Up Promotions for General Practitioners, Dispensing Pharmacies
July 3, 2013
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…